戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 , CAD, and stable angina treated with 1 to 2 antianginals.
2 systemic and coronary beds that subserve the antianginal action of GTN is not known.
3  reduce TDR suggest that, in addition to its antianginal actions, the drug may possess antiarrhythmic
4                        Ranolazine is a novel antianginal agent capable of producing antiischemic effe
5                       Ranolazine is a unique antianginal agent that has been effective in stable angi
6                          Trimetazidine is an antianginal agent that improves energy metabolism of the
7                        Ranolazine is a novel antianginal agent that reduces ischemia in patients with
8                             Ranolazine is an antianginal agent that targets a number of ion channels
9                         Ranolazine (Ran), an antianginal agent, inhibits late Na(+) current.
10                            Ranolazine, a new antianginal agent, reduces ischemic symptoms in patients
11 ssion of ambulatory myocardial ischemia with antianginal agents or revascularization therapy is super
12  78% statins, 89% beta-blockers, average 2.9 antianginal agents).
13 n symptomatic despite treatment with up to 2 antianginal agents.
14 of maximum recommended doses of conventional antianginal agents.
15 evidence of ischemia but no obstructive CAD, antianginal and anti-ischemic therapies can improve symp
16     Ranolazine is a Na(V)1.5 antagonist with antianginal and antiarrhythmic properties.
17                     This study evaluated the antianginal and antiischemic effects of ivabradine, a ne
18                                              Antianginal and lipid-lowering medications may modify th
19 and the odds of antianginal therapy with >=2 antianginals and stress testing did not change (OR, 0.98
20 of >=2 antianginals, stress testing, and >=2 antianginals and stress testing within 3 months of PCI a
21 n shown to be an effective antihypertensive, antianginal, and anti-ischemic agent, and because of its
22 ing arrhythmias and include antiarrhythmics, antianginals, antiemetics, gastrointestinal stimulants,
23 it from intensive medical therapy, including antianginal, antiplatelet, antithrombotic, and statin ag
24                                   Adjunctive antianginal, antiplatelet, antithrombotic, beta blocker,
25 n during follow-up did not fully explain the antianginal benefit of CABG in the overall population.
26  We conducted a randomized trial to test the antianginal benefit of ranolazine in patients with diabe
27           Trimetazidine acts as an effective antianginal clinical agent by modulating cardiac energy
28                   The three major classes of antianginal drug all inhibit platelet aggregation at hig
29 ic pathway was identified as a target of the antianginal drug molsidomine, which may explain its chol
30 DH2) catalyzes vascular bioactivation of the antianginal drug nitroglycerin (GTN) to yield nitric oxi
31 DH2) catalyzes vascular bioactivation of the antianginal drug nitroglycerin (GTN), resulting in activ
32                        We also show that the antianginal drug ranolazine can abolish CO-induced early
33               Ranolazine is a new and unique antianginal drug that has been approved for the treatmen
34 ine, a piperazine derivative and established antianginal drug, is known to reduce intracellular Na(+)
35 nd its alleviation by the most commonly used antianginal drug, nitroglycerin, are incompletely unders
36 tch, or increase of the dose of at least one antianginal drug; or recurrence or persistence of angina
37  to develop a method by which the effects of antianginal drugs could be evaluated invasively during p
38    Randomized or crossover studies comparing antianginal drugs from 2 or 3 different classes (beta-bl
39 od, to evaluate the effect of representative antianginal drugs on platelet function in vivo in health
40 an increase in angina-free walking time with antianginal drugs or revascularization procedures, the r
41 at ivabradine, representing a novel class of antianginal drugs, is effective and safe during 3 months
42 mia and the actions of novel and established antianginal drugs.
43    This study sought to examine ranolazine's antianginal effect in relation to glucose control.
44                          We investigated the antianginal effects of ranolazine in the subgroup of pat
45                           In addition to its antianginal effects, ranolazine has been shown to reduce
46  vivo and thus at least partly underlies the antianginal mechanism of drug action.
47                 Guidelines recommend maximal antianginal medical therapy before attempted coronary ar
48  quality of life, generally after a trial of antianginal medical therapy.
49 table angina who were receiving little or no antianginal medication and had objective evidence of isc
50                    The three main classes of antianginal medication have different and possible clini
51                We also examined the rates of antianginal medication prescriptions at discharge.
52 le coronary artery disease with little or no antianginal medication relieved angina, but residual sym
53  procedure in patients who are not receiving antianginal medication remains unknown.
54 efractory angina and reduction in the use of antianginal medication with early intervention.
55 - and multivessel stable CAD on little or no antianginal medication, the placebo-controlled efficacy
56 oronary artery disease (CAD) on little or no antianginal medication.
57 shown that providers may infrequently adjust antianginal medications (AAMs) following chronic total o
58                                       Use of antianginal medications (beta-adrenergic blockers, nitra
59 terior ischemia (PL), and number of baseline antianginal medications (QL), with more benefit of invas
60 ence interval [CI], -15.22 to -0.41), use of antianginal medications (standardized MD, -0.59; 95% CI,
61 dergoing attempted CTO PCI, 40% received >=2 antianginal medications and 24% underwent preprocedural
62 hospital referral regions in providing >/= 2 antianginal medications and in rates of PCI from the Dar
63                         Patients stopped all antianginal medications and underwent a 2-week symptom a
64 pital referral region and the rates of >/= 2 antianginal medications before PCI (Spearman rho, 0.0277
65           The median rate of providing >/= 2 antianginal medications before PCI was 18.9%.
66 007 on the regions' rates of providing >/= 2 antianginal medications before PCI.
67 to determine whether greater regional use of antianginal medications in PCI patients is associated wi
68 ble if they were unweanable from intravenous antianginal medications or were too unstable for a persa
69  that occurred on a given day, the number of antianginal medications prescribed on that day, and clin
70 na, 15.8% in 2010 and 38.4% in 2014), use of antianginal medications prior to PCI (at least 2 antiang
71  Symptoms of angina were improved and use of antianginal medications significantly reduced with the i
72                                              Antianginal medications were stopped, and daily angina s
73 ociety angina class, exercise tolerance, and antianginal medications), myocardial perfusion, and clin
74 ociety angina class, exercise tolerance, and antianginal medications).
75 anginal medications prior to PCI (at least 2 antianginal medications, 22.3% in 2010 and 35.1% in 2014
76 ogate end points of anginal episodes, use of antianginal medications, Canadian Cardiovascular Society
77                 Following discontinuation of antianginal medications, patients were evaluated prerand
78 d 2.8% of patients were on 0, 1, 2, or >/= 3 antianginal medications, respectively.
79                                              Antianginal medications, such as B-blockers, nitrates, o
80 on did not substantially supplant the use of antianginal medications, which were commonly used despit
81 .26 [1.75-2.80]), as well as for those on no antianginal medications.
82 cy score of <=90) despite treatment with >=3 antianginal medications.
83 ginal episodes despite revascularization and antianginal medications.
84 c heart disease and may obviate the need for antianginal medications.
85  younger age, anterior ischemia, and on more antianginal medications.
86 011, and calculated rates of providing >/= 2 antianginal medicines before PCI.
87 efits were not due to higher rates of use of antianginal medicines or aspirin and were not a conseque
88                         In a previous trial, antianginal monotherapy with ranolazine, a drug believed
89 ide evidence for the use of CSR as a further antianginal option for patients with stable coronary art
90 ast as high as those without DM despite more antianginal prescriptions at discharge.
91 fect on the ET(A) receptor may relate to the antianginal properties of estrogens.
92  using agents with both antihypertensive and antianginal properties.
93 protective hormones and are reported to have antianginal properties.
94 pure Na(+) channel blocker lidocaine and the antianginal ranolazine were additionally tested and also
95 ed exercise capacity and provided additional antianginal relief to symptomatic patients with severe c
96                        Ranolazine is a novel antianginal shown in an exploratory analysis in patients
97                             Ranolazine is an antianginal shown to reduce angina and improve exercise
98 y management before CTO PCI: presence of >=2 antianginals, stress testing, and >=2 antianginals and s
99                                    Designing antianginal therapies that exploit these mechanisms may
100  on angina and quality of life compared with antianginal therapies.
101 ing (71.6%), or suboptimal (</=1 medication) antianginal therapy (95.8%).
102 9 to 1.00; p = 0.048) and intensification of antianginal therapy (HR: 0.77; 95% CI: 0.64 to 0.92, p =
103 tios (MOR) showed substantial variability in antianginal therapy across hospital sites (MOR, 1.3 [95%
104  dysfunction improves survival compared with antianginal therapy alone.
105 in blood pressure, heart rate, or background antianginal therapy and persisted throughout 12 weeks.
106 ency and variability of preprocedural use of antianginal therapy and stress testing within 3 months b
107 ound no association between the intensity of antianginal therapy and the use of PCI across hospital r
108 exist in many regions to increase the use of antianginal therapy before proceeding to elective PCI, a
109                 The efficacy of conventional antianginal therapy in preventing myocardial ischemia in
110                               The effects of antianginal therapy on blood pressure changes during isc
111 cal scenarios revealed baseline symptoms and antianginal therapy to be the primary drivers of health
112 , 0.97 [95% CI, 0.93-0.99]), and the odds of antianginal therapy with >=2 antianginals and stress tes
113                                  The odds of antianginal therapy with more than one medication before
114 percutaneous coronary intervention (PCI) and antianginal therapy.
115 for the safety and efficacy of ranolazine as antianginal therapy.
116 of angina was obtained with increased use of antianginal treatment in 11.1%, with coronary revascular
117 ischemia and their management plan (i.e., no antianginal treatment, medical therapy or an invasive in
118 data have been published comparing these two antianginal treatments in this setting.

 
Page Top